Nasdaq
$18.89▼ 1.92%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.65BShares out 1.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 10.15Pre-market26.10.15 21:006-KKey event#●●●#●●●
Legend Biotech CorpBullish
Legend Biotech announced on October 15, 2026, that the U.S. FDA has cleared its Investigational New Drug (IND) application for LB2501, an investigational in vivo CAR-T therapy for relapsed or refractory B-cell malignancies. LB2501 is the first known dual-targeting in vivo CAR-T therapy designed to generate CD19/CD20 CAR-T cells directly within the patient, with a planned U.S. Phase 1/2 study to follow.…more
$18.89-1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 20:306-KKey event
Legend Biotech Corp
Legend Biotech announced that CARVYKTI generated approximately $710 million in net trade sales for the quarter ended September 30, 2026. This preliminary sales figure is based on information provided by Janssen and remains subject to final financial statement review.…more
$18.89-1.92%vs prev closeView filingShare - 10.7After-hours26.10.08 05:15S-8Offering
Legend Biotech Corp
Legend Biotech Corporation has registered an additional 19,100,000 ordinary shares under its Amended and Restated 2020 Restricted Shares Plan. This registration is intended to facilitate equity-based compensation for employees, consultants, and directors.…more
$18.89-1.92%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:00#●●●#●●●
Legend Biotech Receives FDA Clearance for LB2501 In Vivo CAR-T Therapy
Legend Biotech has received FDA clearance for its IND application to begin U.S. Phase 1/2 clinical trials for LB2501, an in vivo CAR-T therapy. While this marks a milestone for the company's cell engineering platform, the therapy remains in early-stage development.…more
$18.89-1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Pre-market26.10.01 22:00
●●●●●●●● ●●●●● ●●●●●●
Legend Biotech has launched the ELITE grant program to support early-career healthcare professionals in multiple myeloma research. As this is a corporate social responsibility initiative, it does not have a direct impact on the company's financial performance or stock price.…more
$18.89-1.92%vs prev close - 9.25Pre-market26.09.25 20:00
●●●●●●●● ●●●●● ●●●●●●
Legend Biotech announced that 50% of patients in the CARTITUDE-2 study remained progression-free and alive five years after a single infusion of CARVYKTI. While these long-term results support the therapy's durability, they represent clinical progress rather than immediate financial catalysts.…more
$18.89-1.92%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report